London, UK (PRWEB) October 07, 2014
Over the last few decades, the researchers have increased their knowledge about the human immune system, which has resulted in the achievement of considerable amount of regulatory milestones during the period. The use of monoclonal antibodies (mAbs) for the treatment of cancer has grown significantly. The surging availability of these agents on the market has enabled the pharmaceutical companies to create innovative combination approaches that have the ability to provide much greater insights into the immune system so as to develop more effective mAbs.
Over the next ten years, as new cancer-specific proteins are discovered and introduced, newer MAb targets will likely be successfully identified for regulating the growth of tumor cells or inducing apoptosis. In addition, the changes in MAb are also expected to allow for more efficient cytotoxic or radionuclide MAb drug targeting or result in more effective activation of host-effector mechanisms which tend to build better therapeutic antibodies. Cancer monoclonal antibodies' future keeps on showing enormous potential on the back of a soaring number of novel techniques and discoveries. Despite the advancements being made with respect to understanding the complexities of human cells there remains a significant portion of work to be completed.
New cutting-edge report “Global Cancer Monoclonal Antibodies Market & Pipeline Insight” worked out by Kuick Research is now available at MarketPublishers.com.
Title: Global Cancer Monoclonal Antibodies Market & Pipeline Insight
Published: October, 2014
Price: US$ 2,400.00
The report provides a true guide to the world cancer MAbs marketplace. The study provides a comprehensive overview the types of monoclonal antibodies, mechanisms of monoclonal antibodies, as well as the need for monoclonal antibodies for cancer treatment. It then presents a deep overview of the current market scenario with insights into the clinical pipeline; examines the market dynamics, discusses the cancer MAbs pipeline; sheds light on the marketed cancer monoclonal antibodies; as well as reviews the suspended and discontinued monoclonal antibodies pipeline. The competitive landscape analysis including exhaustive profiling of the top 12 players is included, and detailed patent information is revealed the report, too.
Companies covered: Abbvie, Amgen, Bayer HealthCare, Biogen Idec, Eli Lilly, Genmab, Gilead Sciences, GlaxoSmithKline, Novartis, Pfizer, Roche, and Seattle Genetics.
- Comprehensive assessment of the global cancer monoclonal antibodies market and incidence scenario.
- Emerging market dynamics, including favorable parameters, challenges and future growth outlook.
- All-round analysis of the world cancer monoclonal antibodies pipeline by indication, phase, company and country.
- Profound insights into the 605 cancer monoclonal antibodies currently in development stage.
- Up-close look at the 258 mAbs for cancer in pre-clinical phase.
- Comprehensive analysis of the 34 marketed cancer monoclonal antibodies.
- In-depth examination of the major patents, including patent technology and number.
More new studies by the publisher can be found at Kuick Research page.